M ycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma, generally showing an indolent and prolonged clinical history with slow progression over the years from patches to more infiltrated plaques, tumour, and systemic involvement in later stages. Less frequently, it may exhibit a more aggressive behaviour from the beginning ("MF d'emblée"). MF is thought to arise from a background of chronic inflammation as a response to chronic antigenic stimulation, with a series of genetic mutations resulting in stepwise progression from eczematous patches, as in parapsoriasis, to plaques, tumours, and eventually haematogenous dissemination. The molecular events underlying the different clinical courses have been reviewed by Hansen. 1 The pathogenesis of MF is probably related to various factors of exogenous and/or endogenous origin. 2 "Mycosis fungoides is thought to arise from a background of chronic inflammation as a response to chronic antigenic stimulation" Histologically, MF is composed of a dermal infiltrate of neoplastic T cells with cerebriform nuclei showing epidermotropism ranging from single lymphoid T cells linearly arranged at the epidermal basal layer to clusters of cells spreading over all layers and forming classic Pautrier's abscesses. Neoplastic cells typically express the CD3+/CD4+ T helper phenotype; other T cell antigens, such as CD2, CD5, and CD7, can be hypoexpressed or lost in the advanced stages of the disease. [3] [4] [5] [6] Early MF, showing a mild T cell lymphoid infiltrate, is hard to differentiate histologically from superficial dermatosis; diagnosis can be supported by the demonstration of monoclonal rearrangement of T cell receptor (TCR) genes and/or T cell antigen loss. 7 8 There is an ongoing debate on whether these difficult cases should be considered as early lymphoma capable of progression, frustre lymphoma with no risk of evolution, or an altogether different entity unrelated to MF. [9] [10] [11] In addition to neoplastic CD4+ cells, reactive cells are also detected in typical MF lesions, such as T cells staining for CD8 (tumour infiltrating lymphocytes; TILs) and dendritic cells expressing CD1a antigen, both in the epidermis (Langerhan's cells; LCs) and dermis (dermal dendritic cells; DDCs). The role of these cells in the pathogenesis and progression of MF is still unclear. A few studies have focused on the distribution of CD8+ and CD1a+ cells and their relation with clinical behavior in MF, with conflicting results. [12] [13] [14] [15] [16] [17] The aim of our study was to find a correlation, if any, between the density of TILs, LCs, and DDCs and the density, distribution, and epidermotropism of the lymphoid neoplastic infiltrate, with special emphasis on the comparison between early and more advanced MF.
METHODS
We reviewed the records of 46 patients consecutively referred by dermatologists to the Institute of Anatomical Pathology for diagnosis and to the department of haematology (University of Ancona School of Medicine) for staging, treatment, and follow up from 1994 to 2001. Clinical data regarding age, sex, clinical type of lesion, stage, 18 19 treatment, and follow up were obtained from the medical charts. Pretreatment diagnostic biopsy specimens were submitted to histological and immunophenotypical analysis. Skin samples had been received fresh and cut into two halves: one was fixed in formalin and embedded in paraffin wax, and the other frozen in isopentane, cooled in liquid nitrogen, and stored at −80°C.
Haematoxylin and eosin stained sections from formalin fixed and paraffin wax embedded tissues were reviewed to evaluate the morphological features of the disease. The density of the neoplastic infiltrate was scored with a four point scale based on quantity and distribution as follows. Slides were analysed separately by two of us (GG and AF): cases with discordant scores were discussed until an agreement was reached.
Data regarding T cell clonality were obtained by polymerase chain reaction analysis of TCR-γ gene rearrangement on paraffin wax embedded sections, as described previously. 20 Results were subjected to statistical analysis using the StatView 4.5 program. Differences between nominal and continuous variables were evaluated by means of the χ 2 test and the non-parametric Mann-Whitney U and Kruskal Wallis tests, respectively. Significance was set at p < 0.05. Table 2 shows the clinical features of the patients. There were 24 female and 22 male patients, with a median age of 61 years (range, 28-76). Thirty six of the patients showed erythematous scaling skin patches, eight showed plaques, and two had multiple tumours. Seventeen patients had stage IA, 21 stage IB, four stage IIA, two stage IIB, one stage IIIB, and one stage IVA MF. 19 20 Twenty eight patients were treated according to their stage: 22 received a combined protocol with psoralene, ultraviolet A rays, and interferon α 21 ; in one of these patients treatment had to be stopped because of intolerance; three patients were treated with Psoralene and ultraviolet A rays only, two received chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, and one radiotherapy. Five patients were not treated because of a concomitant contraindicating disease (heart disease in four patients and vitiligo in one), 12 patients have not yet started treatment because of recent diagnosis, and one died from unrelated causes before beginning. Of the 28 treated patients, 22 achieved complete clinical remission (CR) with complete clearance of all skin lesions, five achieved partial remission with reduction of the skin lesions of at least 50%, and one patient showed stable disease. During follow up (median time, 26 months; range, 4-78), one patient died of disease six months after beginning treatment; seven of the 22 patients with CR relapsed at a median time of 30 months (range, 11-46) and were treated again with the same protocol, all achieving a second CR.
RESULTS

Clinical features
Histological, immunophenotypical, and PCR results
Eleven patients showed a mild subepidermal lymphoid infiltrate made up of cerebriform atypical cells with a superficial and perivascular distribution, without tendency to confluence ( fig 1A) : these findings were subtle, and differential diagnosis of an early patch MF with superficial dermatitis was supported by the demonstration of an aberrant T cell antigenic profile and/or a monoclonal TCR-γ gene rearrangement. A moderate lymphoid infiltrate in the upper dermis with a perivascular distribution showing tendency to confluence was seen in 15 cases; 16 cases showed a band-like lymphoid infiltrate homogeneously distributed below the dermal-epidermal junction ( fig 1D) , and four cases presented a heavy burden of neoplastic cells extending deeply into the dermis or the hypodermis. Table 2 shows the distribution of all clinical and pathological parameters in the four lymphoid infiltrate grades. The subepidermal lymphoid infiltrate density was found to be associated with many of the clinical parameters. Patients with a grade 1-2 subepidermal lymphoid infiltrate were older than those with grade 3-4 (mean, 62 (SD, 10) and mean 54 (SD, 12), respectively; p = 0.0383) and showed patches in 24 of 26 cases, whereas eight of the 20 patients with grade 3-4 showed plaques or nodules (p = 0.008). Three of four of the patients with a grade 4 lymphoid infiltrate were stage > IIA, whereas 37 of the 42 patients with less than grade 4 were in stage < IIA (p = 0.0015). None of the patients with a nodular pattern showed pronounced epidermotropism, whereas a variable degree of epidermotropism was seen in the other groups.
All MF cases showed neoplastic cells with the typical CD4+ phenotype, with loss of other T cell antigens in 45 cases: CD2 was lost in 44 cases, CD5 in 25, and CD7 in 39. On polymerase chain reaction analysis, 39 cases showed one or two monoclonal bands and seven showed a polyclonal pattern.
The subepidermal lymphoid infiltrate density was significantly associated with the number of CD8+ T cells (p = 0.004; fig 1B-E) ; the density of CD8+ T cells was lower in cases with a grade 1 subepidermal lymphoid infiltrate than in those with grade > 1 (p = 0.001; fig 2) .
The dermal (p = 0.03), but not the epidermal (p = 0.42), CD1a positivity score was significantly associated with the density of the lymphoid infiltrate ( fig 1C-F) ; the density of the dermal CD1a+ dendritic cells was lower in grades 1-2 than in grades 3-4 (p = 0.0057; fig 3) .
Among the studied parameters, only age, clinical type of lesion, stage of disease, and density of subepidermal infiltrate 
DISCUSSION
We found that patients with band-like and nodular subepidermal lymphoid infiltrates were younger, were more likely to have clinical plaques/nodules and be stage > IIA, and were less likely to achieve CR than those with a less dense subepidermal lymphoid infiltrate. TIL and DDC numbers were found to be related only to the subepidermal infiltrate, being lower in less dense neoplastic infiltrates.
At an early stage, MF is very similar immunologically and morphologically to T cell cutaneous reactions; for this reason, it may be difficult to differentiate MF from aspecific superficial dermatosis. These similarities support the hypothesis that MF originates from a neoplastic transformation of T helper cells involved in a cutaneous immunological response. A model based on in vitro experiments has been proposed in which T helper CD4+ cells undergo retroviral infection as a result of the interaction with epidermal LCs, which take the retroviruses up from the infected keratinocytes nearby and transmit them to T cells through antigen presentation on major histocompatibility complex class II molecules. This would result in malignant transformation of the T cells, which become atypical and cerebriform. 22 The close interaction between LC and MF cells is indeed evident in the classic morphologic feature of MF, Pautrier's abscess, which consists of clusters of MF cells adherent to LC dendritic processes within the epidermis. Early in the disease, the MF cells might retain the ability to respond specifically to the retroviral peptides presented as antigens by LCs, thus depending on LCs for proliferation. They are also able to show a response to inhibitory signals. However, with prolonged stimulation, subclones might appear that no longer require antigen dependent stimulation to proliferate, but show a tendency to infiltrate and disseminate. 22 Inhibitory control is exerted by the cytotoxic CD8+ cells, the so called TILs: they are activated by the expression of tumour specific antigens on MF cells, which have the ability to escape the immune control of Fas ligand expression, 23 causing TIL apoptosis through the Fas pathway or inducing the expression of molecules such as killing inhibitor receptors on TILs. 24 The proportion of TILs in MF tends to reduce with the increase in the lymphoid infiltrate. 6 "With prolonged stimulation, subclones might appear that no longer require antigen dependent stimulation to proliferate, but show a tendency to infiltrate and disseminate"
Our data on the density of LCs, DDCs, and TILs are consistent with the above immunological model. Our series is mostly made up of early cases, some showing a mild infiltrate. However, we saw a wide spectrum of disease, with the increase of the lymphoid infiltrate being accompanied by a higher clinical stage and a worse response to treatment. Interestingly, a large proportion of patients with early disease and a mild lymphoid infiltrate showed a lower number of TILs compared with all the other patients. In daily pathology practice, patients like these represent a diagnostic problem between suspicious early MF or indeterminate lymphoid infiltrate. The diagnostic role of clonality and immunophenotypical analysis is still debated because aberrant phenotype and monoclonality have sometimes been described in bona fide reactive dermatoses. 25 The diagnosis should be based on morphological features, such as the presence of lymphocytes with extremely convoluted, medium to large nuclei, single or clustered in the epidermis, and arranged in small sheets in the dermis. 25 All our patients with low numbers of TILs showed the typical histological features of MF and were monoclonal with an aberrant phenotype. A possible explanation for low TIL density in these patients might be the absence of activation as a result of low tumour specific antigen expression in MF cells. Thus, these cases could represent a very early step in MF; the next step could be the activation of TILs after exposure to a great number of tumour specific antigens. There is controversy on the soundness of treating these patients with early disease in the same way as those with more advanced MF. Large studies with long term follow up of patients with different proportions of CD8+ cells like those in our series are needed to clarify whether such patients exhibit a different clinical behaviour. Moreover, we found that cases with a denser lymphoid infiltrate rarely showed low TIL density, a feature strongly suggesting the activation of TILs against tumorous cells. The lack of evidence of TIL suppression in our four patients with a grade 4 subepidermal infiltrate could be related to the small group size, but may also reflect the inability of the neoplastic cells to downregulate antitumour immunity. A preserved immune reaction against tumour cells could explain the improved survival rate described in advanced MF with high numbers of TILs in some series. 13 14 With regard to dendritic cells, we found no significant difference in epidermal LC numbers between groups with different densities of lymphoid infiltrate, suggesting that epidermal LCs could be equally active in all disease phases. Their density was not associated with epidermotropism.
In contrast, a higher DDC density was seen in patients with a band-like and nodular dermal infiltrate. Our data are in line with previous observations 15 26-28 suggesting that, with the progression of the malignancy, DDCs could present tumour specific antigens, derived from apoptotic MF cells, to other reactive T cells, thereby recruiting them. Under unfavourable circumstances, immature dendritic cells could be exposed to maturational blockers directly produced by neoplastic cells, such as interleukin 10, and would fail to become immunogenic, leading to downregulation of antitumour immunity and promoting tumour progression. 29 The possibility of discriminating within the dendritic cell pool between elements at different maturational stages and with different functions could provide interesting information if applied to series with long term follow up. Moreover, the ability to enhance inhibitory dendritic cells and CD8+ TILs at early stages of MF would be an optimal basis for the therapeutic management of these patients, with the aim of suppressing MF cell proliferation and preventing disease progression and dissemination.
In conclusion, the interactions between MF cells and dendritic cells seems to be important both in inducing the proliferation of neoplastic cells and in recruiting reactive CD8+ cells, which are probably activated by the exposure to tumour specific antigens, particularly when the infiltrate increases. Our results suggest that in MF, LC numbers are not associated with the density of neoplastic cells because different infiltrate grades show the same distribution, whereas numbers of TILs and DDCs tend to increase with the accumulation of neoplastic cells, suggesting that they are active against tumorous cells. 
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